Actively Recruiting
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Led by Radboud University Medical Center · Updated on 2025-05-22
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of \[68Ga\]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection. The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like \[68Ga\]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, \[68Ga\]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.
CONDITIONS
Official Title
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The patient is at least 18 years old on the day of inclusion.
- The patient has suspected chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis.
- There is no significant interference with standard care and follow-up.
You will not qualify if you...
- The patient is pregnant or planning on becoming pregnant.
- The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receives dialysis.
- The patient has (chronic) iron overload.
- The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.
- The patient is not able to lie still in the scanner.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
RadboudUMC
Nijmegen, Netherlands
Actively Recruiting
Research Team
L
Laura Michon
CONTACT
R
Roger Brüggemann
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here